Saturday, August 2, 2014

Roth starts Sucampo at buy

Roth starts Sucampo at buy

August 1, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Sucampo Pharmaceuticals (NASDAQ:SCMP) with a “buy” rating and price target of $9. The shares were quoted at $6 in early trading on Friday. “Our positive thesis on Sucampo is based on three tenets,” writes analyst Ed Arce. On Aug. 5, new CEO, Peter Greenleaf, will announce his […]

Leerink starts Flamel Technologies at outperform

Leerink starts Flamel Technologies at outperform

August 1, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Flamel Technologies (NASDAQ:FLML) with an “outperform” rating and 12-month price target of $22. The stock closed at $13.33 on Thursday. Flamel is focused on the development of products delivered via one of its four proprietary technologies: Medusa, Micropump, LiquiTime and Trigger Lock. Analyst Jason Gerberry expects share appreciation […]

Roth starts Alcobra Pharma at buy

Roth starts Alcobra Pharma at buy

August 1, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Alcobra Pharma (NASDAQ:ADHD) with a “buy” rating and $40 price target. The stock closed at $18.02 on Thursday. Alcobra Pharma’s lead product, MDX, an extended release formulation of Metadoxin, is being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). MDX could also have a significant […]

Clarus starts Tekmira Pharma at buy

Clarus starts Tekmira Pharma at buy

July 31, 2014 by · Leave a Comment 

Tweet Clarus Securities has initiated coverage of Tekmira Pharmaceuticals (NASDAQ:TKMR; TSX:TKM) with a “buy” rating and price target of $22.50, saying the company is delivering multiple paths to value. The stock closed at $12.73 on Wednesday. Tekmira is focused on RNA interference (RNAi) therapeutics and is a global leader in the field. The company develops […]

Verisante adds Drs. Beer and Werschler to its CAB

Verisante adds Drs. Beer and Werschler to its CAB

July 29, 2014 by · Leave a Comment 

Tweet Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has appointed Dr. Kenneth Beer and Dr. Wm. Philip Werschler to the company’s clinical advisory board. “Both Dr. Beer and Dr. Werschler have extensive experience assisting companies with setting up scientific advisory boards, advising with clinical studies and navigating the medical device regulatory regime in the U.S.,” Thomas Braun, president […]

FDA clears Lorus Therapeutics IND for LOR-253

FDA clears Lorus Therapeutics IND for LOR-253

July 28, 2014 by · Leave a Comment 

Tweet The FDA has completed its review and cleared Lorus Therapeutics’ (OTC:LRUSF; TSX:LOR) investigational-new-drug application of LOR-253 for the treatment of hematologic malignancies, including acute myeloid leukemia, high-risk myelodysplastic syndromes, lymphomas and multiple myeloma. Clearance of the IND allows Lorus to initiate a Phase 1b, multicenter, open-label, clinical study of LOR-253 in patients with relapsed […]

Roth upgrades Prosensa Therapeutic to buy

Roth upgrades Prosensa Therapeutic to buy

July 28, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded Prosensa Therapeutic NV (NASDAQ:RNA) to “buy,” with a $17 price target, reflecting evolving data in the treatment of Duchenne muscular dystrophy (DMD) and a conciliatory regulatory environment. The stock closed at $9.65 on Friday. Prosensa’s drisapersen treatment for DMD failed a Phase 3 trial last fall, prompting partner GlaxoSmithKline […]

Roth starts CorMedix at buy

Roth starts CorMedix at buy

July 24, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of CorMedix (NYSE:CRMD) with a “buy” rating and $3 price target. The stock closed at $1.94 on Wednesday. “The impetus for our buy rating is the potential of the company’s Neutrolin compound to drive revenues and ultimately profits,” writes analyst Scott Henry. Neutrolin is approved in Europe and […]

HCW sees no impact from IntelGenx management change

HCW sees no impact from IntelGenx management change

July 24, 2014 by · Leave a Comment 

Tweet H.C. Wainwright says the recent management change at IntelGenx Technologies (OTCQX:IGXT; TSX-V:IGX) poses no impact. In a conference call yesterday, interim CEO, Horst Zerbe, reiterated management’s confidence in the continuation of business activities despite the recent departure of previous CEO, Rajiv Khosla, writes analyst Swayampakula Ramakanth. “With the founder at the helm, we are […]

Leerink starts Zafgen at outperform

Leerink starts Zafgen at outperform

July 23, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Zafgen (NASDAQ:ZFGN) with an “outperform” rating and a $35 price target. The stock closed at $18.19 on Wednesday. Zafgen is developing its lead product, beloranib, in two rare forms of obesity: Prader-Willi Syndrome (PWS) and Craniopharyngioma-Associated Obesity (CAO), each of which present severe orphan unmet-medical needs with an […]

Next Page »

Email Newsletters with Constant Contact
Google+